Liquid Biopsy Before Tissue Biopsy Reveals More Biomarkers in NSCLC
Performing liquid biopsy before tissue biopsy reveals more biomarkers in patients with non-small cell lung cancer, a study suggests.
Non-Small Cell Lung Cancer
Long-Term Survival With First-Line Nivolumab/Ipilimumab in NSCLC
More than one-third of patients with non-small cell lung cancer treated upfront with nivolumab plus ipilimumab were alive at 3 years.
NSCLC Driving Increase in Stage I Lung Cancer Diagnoses
The incidence of stage I lung cancer increased between 2010 and 2017, according to data from more than 1.4 million US patients with lung cancer.
FDA Passes on Poziotinib for NSCLC With HER2 Exon 20 Insertions
The FDA has issued a complete response letter to Spectrum Pharmaceuticals regarding the new drug application for poziotinib.
Homeopathic Add-On Improves QOL, Survival in Non-Small Cell Lung Cancer
Homeopathic treatment may improve quality of life and survival among patients with stage III-IV non-small cell lung cancer who are receiving chemotherapy.
Aprepitant Better Than Desloratadine for TKI-Induced Pruritus
A prospective study compared aprepitant with desloratadine for the relief of treatment-induced pruritus in patients with lung cancer treated with EGFR-TKIs.
Are There Factors Associated With Lung Cancer Stage at Diagnosis?
While the rate of late-stage NSCLC diagnosis is improving, more needs to be done to increase survival rates. Are there outside factors that affect the stage at diagnosis, and what can we learn from them?
Adding Tremelimumab and Durvalumab to Chemo Improves PFS, OS in mNSCLC
Adding tremelimumab and durvalumab to chemotherapy improves progression-free survival and overall survival in patients with metastatic non-small cell lung cancer, phase 3 data suggest.
Predicting Outcomes in NSCLC Patients Treated With Immunotherapy or Immunochemotherapy
Researchers have identified factors associated with survival outcomes in NSCLC patients treated with immunotherapy or immunochemotherapy.
Imjudo Plus Imfinzi and Chemotherapy Approved for Metastatic NSCLC
The approval was based on data from the phase 3 POSEIDON study.
- Loading...
Loading...
Next post in Lung Cancer
Loading... 
Loading...